|
1
|
Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villanueva A: Hepatocellular carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lechel A and Gougelet A: Early HCC treatment: A future strategy against interferon/miR-484 axis to revert precancerous lesions? Gut. 65:1073–1074. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kudo M: Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol. 3 (Suppl 2):S144–S148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 28:3994–4005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Philips GK and Atkins M: Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 27:39–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rowshanravan B, Halliday N and Sansom DM: CTLA-4: a moving target in immunotherapy. Blood. 131:58–67. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al KEYNOTE-224 investigators, : Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD and Kelley RK: Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 125:3234–3241. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu LX, Ling Y and Wang HY: Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2:62018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ringelhan M, Pfister D, O'Connor T, Pikarsky E and Heikenwalder M: The immunology of hepatocellular carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han Q, Zhao H, Jiang Y, Yin C and Zhang J: HCC-derived exosomes: Critical player and target for cancer immune escape. Cells. 8:5582019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tanimine N, Ohira M, Tahara H, Ide K, Tanaka Y, Onoe T and Ohdan H: Strategies for deliberate induction of immune tolerance in liver transplantation: From preclinical models to clinical application. Front Immunol. 11:16152020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, et al: Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology. 153:812–826. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao Y and Yu D: Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 221:1077532021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngambenjawong C, Gustafson HH and Pun SH: Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 114:206–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, et al: A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 24:1178–1191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, Bassez A, Decaluwé H, Pircher A, Van den Eynde K, et al: Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 24:1277–1289. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu XN, Cui DN, Li YF, Liu YH, Liu G and Liu L: Multiple ‘Omics’ data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol. 25:4199–4212. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E, et al: Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One. 8:e640162013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou W, Ma Y, Zhang J, Hu J, Zhang M, Wang Y, Li Y, Wu L, Pan Y, Zhang Y, et al: Predictive model for inflammation grades of chronic hepatitis B: Large-scale analysis of clinical parameters and gene expressions. Liver Int. 37:1632–1641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robinson MD, McCarthy DJ and Smyth GK: edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4:32003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ito K and Murphy D: Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. 2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 356:11–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lorent M, Giral M and Foucher Y: Net time-dependent ROC curves: A solution for evaluating the accuracy of a marker to predict disease-related mortality. Stat Med. 33:2379–2389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Blanche P, Dartigues JF and Jacqmin-Gadda H: Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 32:5381–5397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pontén F, Jirström K and Uhlen M: The Human Protein Atlas--a tool for pathology. J Pathol. 216:387–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang B, Su X, Xie Z, Ding H, Wang T, Xie RY and Wen Z: Inositol-requiring kinase 1 regulates apoptosis via inducing endoplasmic reticulum stress in colitis epithelial cells. Dig Dis Sci. 66:3015–3025. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iñarrairaegui M, Melero I and Sangro B: Immunotherapy of hepatocellular carcinoma: Facts and hopes. Clin Cancer Res. 24:1518–1524. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rizvi S, Wang J and El-Khoueiry AB: Liver cancer immunity. Hepatology. 73 (Suppl 1):86–103. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Finn OJ: Cancer immunology. N Engl J Med. 358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jeong JY, Kim TB, Kim J, Choi HW, Kim EJ, Yoo HJ, Lee S, Jun HR, Yoo W, Kim S, et al: Diversity in the extracellular vesicle-derived microbiome of tissues according to tumor progression in pancreatic cancer. Cancers (Basel). 12:23462020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, et al: Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep. 8:62202018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McGreal EP, Miller JL and Gordon S: Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol. 17:18–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li GZ, Deng JF, Qi YZ, Liu R and Liu ZX: COLEC12 regulates apoptosis of osteosarcoma through Toll-like receptor 4-activated inflammation. J Clin Lab Anal. 34:e234692020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang LL, Hsu WH, Kao MC, Chou CC, Lin CC, Liu CJ, Weng BC, Kuo FC, Kuo CH, Lin MH, et al: Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases. Sci Rep. 8:38212018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W and Schmitz G: Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med (Berl). 84:1055–1066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Andrianifahanana M, Moniaux N and Batra SK: Regulation of mucin expression: Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 1765:189–222. 2006.PubMed/NCBI
|
|
45
|
Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K and Koono M: Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: A possible modulatory role in natural killer cytotoxicity. Am J Pathol. 154:457–468. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shapiro SD and Senior RM: Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol. 20:1100–1102. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C and Gumenscheimer M: The role of the liver in the response to LPS: Experimental and clinical findings. J Endotoxin Res. 8:319–327. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Haque TR and Barritt AS IV: Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol. 30:133–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wiest R, Albillos A, Trauner M, Bajaj JS and Jalan R: Targeting the gut-liver axis in liver disease. J Hepatol. 67:1084–1103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jiang JW, Chen XH, Ren Z and Zheng SS: Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int. 18:19–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, et al: The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 368:973–980. 2020. View Article : Google Scholar : PubMed/NCBI
|
